CrownBio Enhances Its European Capabilities with New Generation of Innovative Translational Models for Obesity and Diabetes
(Santa Clara, Calif., October 11, 2017) — Crown Bioscience, a wholly-owned subsidiary of Crown Bioscience International (TWSE: ticker 6554) and a global drug discovery and development services company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research, announces the availability of their proprietary FATZO™ model in a European based laboratory. The establishment of this improved translational model provides the European scientific community with unfettered access to an advanced research tool for use in preclinical studies of obesity, dysmetabolism and type 2 diabetes.
The FATZO™ is a next generation preclinical research model for obesity, metabolic disorders, diabetes and related complications. The unique feature of an intact leptin system enables the FATZO model to provide novel scientific insights into the physiological and cellular mechanisms that lead from obesity / metabolic disorders to diabetes. It examines polygenic causes of obesity and mimics human pathophysiology by exhibiting metabolic patterns of hyperglycemia and hyperinsulinemia.
“Obesity and diabetes have a significant global impact, affecting more than 422 million people worldwide. We expanded our FATZO™ model to ensure European researchers have ready access to the best translational tools available to advance the drug development programs aimed at curing these diseases,” said Jim Wang, M.D., Crown Bioscience’s Senior Vice President Cardiovascular and Metabolic Diseases (CVMD) Research.
“The establishment of our FATZO™ model in Europe is pivotal to Crown Bioscience’s commitment to providing translational models that are representative of human conditions of obesity, type 2 diabetes and related comorbidities,” said Jean-Pierre Wery, Ph.D., CEO of Crown Bioscience. “We look forward to working with European scientists to help answer their most challenging questions about these diseases and enable more effective drug discovery for their treatment.”
For more information on CrownBio’s commitment to advance the field of cardiovascular and metabolic drug discovery, visit https://www.crownbio.com/cvmd.
Crown Bioscience is a global drug discovery and development solutions company providing translational platforms to advance oncology, inflammation and metabolic disease research. With an extensive portfolio of relevant models and predictive tools, Crown Bioscience enables clients to deliver superior clinical candidates.
Contact details
-
- Louise Stenson
-
Crown Bioscience Company Inquiries
Communications Manager - louise.stenson@crownbio.com
Related topics
Related news
Crown Bioscience Achieves CAP 15189 Accreditation; ISO 15189 Standard for Quality Medical Laboratory Services
Crown Bioscience today announced the dual attainment of College of American Pathologists (CAP) accreditations for its medical laboratory services.
Crown Bioscience Introduces OrganoidXplore: Revolutionizing Cancer Research with Rapid Large-scale Organoid Drug Scre...
Crown Bioscience has launched OrganoidXplore, a revolutionary platform for large-scale screening of patient-derived organoids that accelerates preclinical oncology drug discovery. The platform repl...
Indivumed Services’ Hamburg Site Receives College of American Pathologists (CAP) Accreditation
Indivumed Services GmbH, a Crown Bioscience company, has received laboratory accreditation from the College of American Pathologists (CAP), highlighting its commitment to excellence in laboratory s...
Crown Bioscience Enables HanX Biopharmaceutical to Progress HX009 to Clinical Trials
Crown Bioscience collaborates with HanX Biopharmaceutical, enabling the progression of HX009 to clinical trials for the treatment of lymphoma. The study demonstrates the efficacy of HX009 in target...
Crown Bioscience Announces Transaction Closing of Indivumed’s Service Business and Supporting Biobank
Crown Bioscience, a global contract research organization (CRO) and JSR Life Sciences company, announced today that it has completed its acquisition of the IndivuServ business unit of Indivumed Gmb...